Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of Cullinan Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Cullinan Therapeutics, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Cullinan Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 31 Dec 2025 was $408,730,000, a 31% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

Cullinan Therapeutics, Inc. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $408,730,000 -$181,598,000 -31% 31 Dec 2025 10-K 10 Mar 2026 2025 FY
Q3 2025 $451,369,000 -$176,493,000 -28% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $492,146,000 -$164,075,000 -25% 30 Jun 2025 10-Q 06 Nov 2025 2025 Q3
Q1 2025 $551,839,000 +$126,174,000 +30% 31 Mar 2025 10-Q 06 Nov 2025 2025 Q3
Q4 2024 $590,328,000 +$136,433,000 +30% 31 Dec 2024 10-K 10 Mar 2026 2025 FY
Q3 2024 $627,862,000 +$159,045,000 +34% 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $656,221,000 +$156,647,000 +31% 30 Jun 2024 10-Q 06 Nov 2025 2025 Q3
Q1 2024 $425,665,000 -$59,984,000 -12% 31 Mar 2024 10-Q 06 Nov 2025 2025 Q3
Q4 2023 $453,895,000 -$81,134,000 -15% 31 Dec 2023 10-K 10 Mar 2026 2025 FY
Q3 2023 $468,817,000 -$117,311,000 -20% 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $499,574,000 -$105,044,000 -17% 30 Jun 2023 10-Q 07 Nov 2024 2024 Q3
Q1 2023 $485,649,000 +$66,179,000 +16% 31 Mar 2023 10-Q 07 Nov 2024 2024 Q3
Q4 2022 $535,029,000 +$109,655,000 +26% 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $586,128,000 +$140,654,000 +32% 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $604,618,000 +$146,078,000 +32% 30 Jun 2022 10-Q 08 Nov 2023 2023 Q3
Q1 2022 $419,470,000 -$50,229,000 -11% 31 Mar 2022 10-Q 08 Nov 2023 2023 Q3
Q4 2021 $425,374,000 +$225,059,000 +112% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q3 2021 $445,474,000 +$355,963,000 +398% 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $458,540,000 +$359,621,000 +364% 30 Jun 2021 10-Q 14 Nov 2022 2022 Q3
Q1 2021 $469,699,000 +$362,930,000 +340% 31 Mar 2021 10-Q 14 Nov 2022 2022 Q3
Q4 2020 $200,315,000 +$102,450,000 +105% 31 Dec 2020 10-K 09 Mar 2023 2022 FY
Q3 2020 $89,511,000 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $98,919,000 30 Jun 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2020 $106,769,000 31 Mar 2020 10-Q 09 Nov 2021 2021 Q3
Q4 2019 $97,865,000 31 Dec 2019 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.